If you’ve spent any time developing Java applications, you know IntelliJ IDEA is an absolute powerhouse. It’s the IDE of choice for countless professionals, lauded for its intelligent code completion, ...

Use Spring MVC MultipartFile, Java Path APIs and the browser fetch API to upload files asynchronously and save them safely on the server. Follow the essential steps to download Java 21, configure ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

Companies are scrambling to deal with the glut. Credit...Mojo Wang Supported by By Mike Isaac and Erin Griffith Reporting from San Francisco When a financial services company recently began using ...

Anthropic accidentally leaked part of the internal source code for its coding assistant Claude Code, according to a spokesperson. The leak could help give software developers, and Anthropic's ...

The entire source code for Anthropic’s Claude Code command line interface application (not the models themselves) has been leaked and disseminated, apparently due ...

With Claude enjoying a moment of newfound popularity among regular people, Anthropic is previewing an update designed to make its chatbot better at explaining some concepts. Starting today, Claude can ...

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

Feb 26 (Reuters) - Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares of the U.S.-based drug developer at $16 each. The offering ...

Generate Biomedicines Inc. raised $400 million in an initial public offering, pricing its shares at the midpoint of the marketed range. The Somerville, Massachusetts-based drug developer sold 25 ...